Heartflow (NASDAQ:HTFL) Stock Rating Upgraded by Zacks Research

Key Points

• Heartflow's rating has been upgraded to a "hold" by Zacks Research, with a consensus rating of "Moderate Buy" across various analysts.
• Recent analyst reports include price targets ranging from $35.00 to $38.00, indicating a favorable outlook for the stock.
• Heartflow's stock performance shows a 1-year low of $26.56 and a 1-year high of $36.68, with shares opening at $34.08.

Heartflow (NASDAQ:HTFL - Get Free Report) was upgraded by equities researchers at Zacks Research to a "hold" rating in a research note issued to investors on Wednesday, September 3rd,Zacks.com reports.

A number of other equities analysts have also recently weighed in on HTFL. JPMorgan Chase & Co. began coverage on shares of Heartflow in a research report on Tuesday, September 2nd. They set an "overweight" rating and a $36.00 price target on the stock. Piper Sandler began coverage on shares of Heartflow in a research report on Tuesday, September 2nd. They set an "overweight" rating and a $38.00 price target on the stock. Wall Street Zen raised shares of Heartflow to a "hold" rating in a research report on Saturday, August 16th. Stifel Nicolaus began coverage on shares of Heartflow in a research report on Tuesday, September 2nd. They set a "buy" rating and a $35.00 price target on the stock. Finally, Canaccord Genuity Group began coverage on shares of Heartflow in a research report on Tuesday, September 2nd. They set a "buy" rating and a $35.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.80.

Heartflow Stock Down 0.7%

HTFL stock traded down $0.23 during midday trading on Wednesday, reaching $34.47. The company's stock had a trading volume of 111,938 shares, compared to its average volume of 541,151. Heartflow has a 52 week low of $26.56 and a 52 week high of $36.68.

Heartflow Company Profile

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.